According to IQVIA MAT July 2025 data, Rivaroxaban for Oral Suspension, 1 mg/mL (RLD Xarelto) had estimated annual sales of USD 11 million in the US. Shares of Lupin Ltd ended at ₹1,920.95, down by ₹10.20, or 0.53%, on the BSE.
According to IQVIA MAT July 2025 data, Rivaroxaban for Oral Suspension, 1 mg/mL (RLD Xarelto) had estimated annual sales of USD 11 million in the US. Shares of Lupin Ltd ended at ₹1,920.95, down by ₹10.20, or 0.53%, on the BSE.